Fifteen patients (30%) had ER-positive HER2-negative breast cancer, 17 (35%) had HER2-positive disease, of whom 5 were also ER-positive, and 17 (35%) had triple-negative breast cancer (TNBC). Here, ESR1 is linked to triple-negative breast carcinoma.